Participant Profile: Reset Therapeutics - The Hive

Participant profile: Reset Therapeutics

Using a platform directed toward molecular targets
across the therapeutic spectrum



Participant Profile: Reset Therapeutics logo - The Hive



Reset Therapeutics is an integrated discovery and development company with a therapeutic platform that can be directed toward molecular targets across the therapeutic spectrum. The company’s mission is to discover and develop new drugs to treat human disease by restoring normal circadian clock function.


Enter your email address to follow The Hive and get the latest updates on participants and milestones


Designing therapeutics that treat disease by restoring the body’s natural circadian rhythms

Reset is pioneering first-in-class approaches to treating diseases by restoring the body’s natural 24-hour, or circadian, rhythms. More than half of the best-selling drugs in the US and more than 100 of the WHO essential medicines target rhythmic proteins, but Reset is the first company built exclusively to design clock-modifying therapeutics.

Circadian rhythms can influence sleep-wake cycles, hormone release, body temperature, and other important bodily functions. Chronic disruption of molecular clocks contributes to disease, while a variety of lifestyles/behaviors and chronic disease states disrupt circadian function. These disruptions disconnect physiological needs from environmental cues. Adverse changes in hormonal, behavioral and cellular rhythms are hallmarks of cardiometabolic, CNS and inflammatory disorders, some cancers, and senescence.

Reset’s most advanced drug discovery programs target orphan metabolic and CNS disorders, the latter in partnership with Alkermes. Reset is also pursuing novel therapies to address excessive daytime sleepiness in Parkinson’s disease with funding from The Michael J. Fox Foundation.

Combining the expertise of leaders in science and business

Reset was co-founded by leaders in the field of circadian biology and Bay City Capital. The company is comprised of a highly skilled and educated team of scientists, inventors, entrepreneurs, and visionaries.

Meet the team

Ross Bersot, CFA President and CEO - The Hive | Elsevier

Ross Bersot, CFA
President and CEO

Ross founded Reset Therapeutics in 2008 with Dr. Ronald Evans of the Salk Institute and Drs. Joseph Takahashi and Masashi Yanagisawa from the University of Texas Southwestern Medical Center. Prior to co-founding Reset, Mr. Bersot served as a Managing Director of Bay City Capital, where he focused on investment opportunities in visionary biopharmaceutical and technology companies.

We hope to bring breakthrough treatments to patients in need. Access to the Elsevier Solutions will inform our decision-making process, and hopefully, our chances of developing safe and effective new drugs.

Paul Humphries, Ph.D.
  Head of Drug Discovery - The Hive | Elsevier

Paul Humphries, Ph.D.
Head of Drug Discovery

Paul joined Reset Therapeutics as the Head of Drug Discovery at Reset Therapeutics after serving as a Senior Principal Scientist at Pfizer. where he worked in the area of Metabolic Diseases.

Given the fact that Reset is a phenotypic, disease-area agnostic research company it is important to have access to all of the top scientific journals offered by ScienceDirect. In my previous life as chemist I also enjoyed using Reaxys and it’s great to have access to this excellent resource once again. Going forward, I look forward to utilizing Pathway Studio in order to better mine information related to our current mechanisms of action.

Jamie Cope, Ph.D.
  Director, Translational Medicine - The Hive | Elsevier

Jamie Cope, Ph.D.
Director, Translational Medicine

Jamie is responsible for coordinating the process of moving Reset’s lead Cryptochrome modulator program from proof of concept to IND submission and early to mid-stage clinical development.

Since having had the opportunity of using Elsevier’s Hive, I can already appreciate the convenience and power of a coordinated set of tools built on Elsevier’s growing dominance. To offer one concrete example, some years ago I spent more time and more emails than I care to admit in the ultimately unsuccessful search for a 1970’s era monograph on a grandfathered therapeutic polymer. In less than five minutes on PharmaPendium in The Hive, I found it.

Tod Steinfeld
  Senior Principal Scientist - The Hive | Elsevier

Tod Steinfeld
Senior Principal Scientist

Tod is currently the biology lead for the orexin program for the treatment of narcolepsy. He made the initial discovery of orexin receptor allosteric modulators at Reset as part of an NIH-funded grant for narcolepsy and he continues to further characterize these molecules.

The immediate access to top scientific journals offered by ScienceDirect is important in maintaining pace for a nimble and cutting-edge research organization.

Melissa Fleury
  Scientist - The Hive | Elsevier

Melissa Fleury
Scientist

Melissa is a medicinal chemist with 13 years of experience in the pharmaceutical industry. Before joining Reset Therapeutics, she worked at Gilead, Theravance and MyoKardia, where she contributed to bioactive molecules synthesis and design for treating diseases affecting the liver, heart, lung and intestine.

I used Reaxys to help us design synthetic route more efficiently. I see a great benefit for early-stage companies to partake in The Hive and have access to Pathway Studio, Embase, PharmaPendium, Reaxys, and ScienceDirect. The Hive will definitely help with R&D productivity, efficiency and organization.

The Hive provides a coordinated set of tools to empower the Reset team’s research

"Given the fact that Reset is a phenotypic, disease-area agnostic research company, it is important to have access to all of the top scientific journals offered by ScienceDirect. In my previous life as chemist, I also enjoyed using Reaxys and it’s great to have access to this excellent resource once again. Going forward, I look forward to utilizing Pathway Studio in order to better mine information related to our current mechanisms of action." Paul Humphries, PhD, Head of Drug Discovery
"As of now, I used Reaxys to help us design synthetic route more efficiently. I see a great benefit for early-stage companies to partake in The Hive and have access to Pathway Studio, Embase, PharmaPendium, Reaxys, and ScienceDirect. The Hive will definitely help with R&D productivity, efficiency and organization." Melissa Fleury, Scientist
"The immediate access to top scientific journals offered by ScienceDirect is important in maintaining pace for a nimble and cutting-edge research organization." Tod Steinfeld, Senior Principal Scientist

Blog: Pharma R&D Today

The Hive Welcomes Promising Cancer Treatments

Posted on October 20th, 2016 by Betsy Davis in Pharma R&D
Drug discovery and development was once a very secretive process where the major industry players were intent on keeping their research to themselves in order to stay competitive. Continue reading The Hive Welcomes Promising Cancer Treatments »

Read more blog posts about Reset Therapeutics

Videos and media

Coming soon

Learn more about Elsevier's R&D solutions for drug discovery
and development utilized by Reset Therapeutics:

Reaxys

Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Learn more

Reaxys Medicinal Chemistry

Empower hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Learn more

Embase

Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Learn more

PharmaPendium

Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Learn more

ScienceDirect

Enable researchers to more effectively and efficiently search authoritative, full-text scientific, technical and health content through the use of smart, intuitive functionality.
Learn more

Pathway Studio

Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Learn more

Scopus

Help researchers discover trends, partners and experts with the world’s largest abstract & citation database of peer-reviewed literature, including tools to track, analyze and visualize research.
Learn more